Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial

被引：0
|
作者：
Hart, R. G. [1 ]
Eikelboom, J. [2 ]
Yusuf, S. [3 ]
Gao, P. [3 ]
Paolasso, E. [4 ]
De Caterina, R. [5 ]
Husted, S. [6 ]
Connolly, S. J. [2 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina
[5] Univ Cardiol Div Chieti, Chieti, Italy
[6] Aarhus Univ, Aarhus, Denmark
来源：
EUROPEAN HEART JOURNAL | 2011年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of edoxaban in patients with atrial fibrillation (AF) and severe chronic kidney disease (CKD)
    Lamaida, Norman
    Torella, Giorgio
    Cerciello, Antonio
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N25 - N26
  • [2] Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation - The ARISTOTLE-J Study
    Ogawa, Satoshi
    Shinohara, Yukito
    Kanmuri, Kazuhiro
    [J]. CIRCULATION JOURNAL, 2011, 75 (08) : 1852 - 1859
  • [3] Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease
    Bhatia, Harpreet S.
    Bailey, Joseph
    Unlu, Ozan
    Hoffman, Katherine
    Kim, Robert J.
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2019, 42 (11): : 1463 - 1470
  • [4] Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease
    Bhatia, Harpreet S.
    Bailey, Joseph
    Unlu, Ozan
    Kim, Robert J.
    [J]. CIRCULATION, 2018, 138
  • [5] THE SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION: A META-ANALYSIS
    Chopra, Rebaika
    Kohli, Varun
    Jim, Belinda
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (05) : 664 - 665
  • [6] Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
    Eikelboom, John W.
    Connolly, Stuart J.
    Gao, Peggy
    Paolasso, Ernesto
    De Caterina, Raffaele
    Husted, Steen
    O'Donnell, Martin
    Yusuf, Salim
    Hart, Robert G.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2012, 21 (06): : 429 - 435
  • [7] Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
    Lam, Sum
    [J]. CARDIOLOGY IN REVIEW, 2013, 21 (04) : 207 - 212
  • [8] COMPARATIVE EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
    Gorbatenko, V. S.
    Gerasimenko, A. S.
    Shatalova, O., V
    [J]. KARDIOLOGIYA, 2020, 60 (09) : 102 - 109
  • [9] Safety and Efficacy of Atrial Fibrillation Ablation in Patients With Chronic Kidney Disease
    Abualsuod, Amjad
    Habash, Fuad
    Khaled, Khaldia
    Gheith, Zaid
    Alqam, Bilal
    Madmani, Mohammed Eid
    Vallurupalli, Srikanth
    Maskoun, Waddah
    [J]. CIRCULATION, 2019, 140
  • [10] Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation
    Stamellou, Eleni
    Floege, Juergen
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (10) : 1683 - 1689
12345